


**Listing of Claims**

1. (Original) A compound of the formula I:



I

wherein:

R<sup>1</sup> is selected from the group consisting of:

- (1) -C<sub>1-6</sub>alkyl,
- (2) -C<sub>2-6</sub> alkenyl,
- (3) -C<sub>2-6</sub> alkynyl,

wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl, which is unsubstituted or substituted with a group selected from:

- (i) halo,
- (ii) -C<sub>1-6</sub>alkyl,
- (iii) -C<sub>2-6</sub> alkenyl,
- (iv) -C<sub>2-6</sub> alkynyl,
- (v) -OH, and
- (vi) -O-C<sub>1-6</sub>alkyl,

(4) hydrogen;

R<sup>2</sup> is selected from the group consisting of:

- (1) R<sup>4</sup>-S(O)<sub>2</sub>N(R<sup>7</sup>)-,

wherein R<sup>4</sup> is independently selected from the group consisting of:

- (a) -C<sub>1-6</sub>alkyl,
- (b) -C<sub>2-6</sub> alkenyl,
- (c) -C<sub>2-6</sub> alkynyl,


wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with 1-6 fluoro,

- (d) phenyl, and
- (e) benzyl,

wherein R<sup>7</sup> is independently selected from the group consisting of:

- (a) hydrogen,
- (b) -C<sub>1-6</sub>alkyl,
- (c) -C<sub>2-6</sub> alkenyl,
- (d) -C<sub>2-6</sub> alkynyl,


(2)



wherein R<sup>8a</sup> and R<sup>8b</sup> are independently selected from the group consisting of:

- (a) hydrogen,
- (b) -CN,
- (c) halo,
- (d) -C<sub>1-6</sub>alkyl,
- (e) -C<sub>2-6</sub> alkenyl, and
- (f) -C<sub>2-6</sub> alkynyl

R<sup>3</sup> is selected from the group consisting of:



R<sup>6a</sup>, R<sup>6b</sup>, and R<sup>6c</sup> are independently selected from the group consisting of:

- (1) hydrogen, and
- (2) halogen;

R<sup>5</sup> is selected from the group consisting of:

- (1) -C<sub>1-6</sub>alkyl,
- (2) -C<sub>2-6</sub> alkenyl,
- (3) -C<sub>2-6</sub> alkynyl,

wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with

phenyl, and  
(4) hydrogen;

R<sup>13</sup> is selected from the group consisting of -CH=CH- and -O-;

R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of:

(1) hydrogen,  
(2) C<sub>1-6</sub>alkyl,  
(3) C<sub>2-6</sub> alkenyl,  
(4) C<sub>2-6</sub> alkynyl, wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl,

or R<sup>9</sup> and R<sup>10</sup> may be joined together to form a pyrrolidine or piperidine ring which is unsubstituted or substituted with -C<sub>1-6</sub>alkyl, -C<sub>2-6</sub> alkenyl, -C<sub>2-6</sub> alkynyl, -C<sub>1-6</sub>alkyl-O-C<sub>1-6</sub>alkyl, phenyl or pyridyl;

R<sup>11</sup> is selected from the group consisting of:

(1) -OH,  
(2) -O-C<sub>1-6</sub>alkyl,  
(3) -O-C<sub>1-6</sub>alkyl-phenyl,  
(4) -O-phenyl, and  
(5) phenyl;


R<sup>12</sup> is selected from the group consisting of:

(1) -NR<sup>9</sup>R<sup>10</sup>, and  
(2) -OH;

m is independently 0, 1, or 2;

and pharmaceutically acceptable salts thereof.

2. (Original) The compound of Claim 1 of the formula II:



II

wherein:

$R^1$  is selected from the group consisting of:

- (1)  $C_{1-6}$ alkyl, unsubstituted or substituted with phenyl, and
- (2) hydrogen;

$R^2$  is selected from the group consisting of:

- (1)  $R^4$ -S(O)2N( $R^7$ )-,


wherein  $R^4$  is independently selected from the group consisting of:

- (a)  $C_{1-6}$ alkyl, which is unsubstituted or substituted with 1-6 fluoro,
- (b) phenyl, and
- (c) benzyl,

wherein  $R^7$  is independently selected from the group consisting of:

- (a) hydrogen, and
- (b)  $-C_{1-6}$ alkyl,

(2)



wherein  $R^{8a}$  and  $R^{8b}$  are independently selected from the group consisting of:

- (a) hydrogen,
- (b) -CN,
- (c) halo, and
- (d)  $-C_{1-6}$ alkyl,

$R^5$  is selected from the group consisting of:

- (1)  $C_{1-6}$ alkyl, unsubstituted or substituted with phenyl, and
- (2) hydrogen;

$R^9$  and  $R^{10}$  are independently selected from the group consisting of:


- (1) hydrogen, and
- (2)  $C_{1-6}$ alkyl, unsubstituted or substituted with phenyl;

$R^{11}$  is selected from the group consisting of:

- (1) -OH,
- (2) -O-phenyl, and

(3) phenyl.

3. (Original) The compound of Claim 1 of the formula III:



wherein:

R<sup>1</sup> is selected from the group consisting of:

- (1) C<sub>1-6</sub>alkyl, unsubstituted or substituted with phenyl, and
- (2) hydrogen;

R<sup>2</sup> is selected from the group consisting of:

- (1) R<sup>4</sup>-S(O)₂N(R<sup>7</sup>)-,


wherein R<sup>4</sup> is independently selected from the group consisting of:

- (a) C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with 1-6 fluoro,
- (b) phenyl, and
- (c) benzyl,

wherein R<sup>7</sup> is independently selected from the group consisting of:

- (a) hydrogen, and
- (b) -C<sub>1-6</sub>alkyl,

(2)



wherein R<sup>8a</sup> and R<sup>8b</sup> are independently selected from the group consisting of:

- (a) hydrogen,
- (b) -CN,
- (c) halo, and
- (d) -C<sub>1-6</sub>alkyl,

R<sup>5</sup> is selected from the group consisting of:

- (1) C<sub>1</sub>-6alkyl, unsubstituted or substituted with phenyl, and
- (2) hydrogen;

R<sup>11</sup> is selected from the group consisting of:

- (1) -OH,
- (2) -O-phenyl, and
- (3) phenyl.

4. (Original) The compound of Claim 1 wherein R<sup>1</sup> is selected from the group consisting of:

- (1) benzyl,
- (2) phenyl-ethyl-,
- (3) methyl, and
- (4) hydrogen.

5. (Original) The compound of Claim 1 wherein R<sup>2</sup> is CH<sub>3</sub>-S(O)<sub>2</sub>N(CH<sub>3</sub>)-.

6. (Original) The compound of Claim 1 wherein R<sup>2</sup> is cyano-phenyl-.


7. (Original) The compound of Claim 1 wherein R<sup>5</sup> is methyl.


8. (Original) The compound of Claim 1 wherein R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of:

- (1) hydrogen, and
- (2) methyl.

9. (Original) The compound of Claim 1 wherein R<sup>11</sup> is -OH.

10. (Original) A compound which is selected from the group consisting of:





and pharmaceutically acceptable salts thereof.

11. (Original) A pharmaceutical composition comprising an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. (Original) A method for inhibition of beta-secretase activity in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

13. (Original) A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

14. (Original) A method for preventing, controlling, ameliorating or reducing the risk of Alzheimers disease in a patient in need thereof comprising administering to the patient an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.